Keywords: Amylin, Bristol-Myers, AstraZeneca, M&A, Type 2 diabetes, Byetta, Bydureon, Eli Lilly

Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action

Article | 02 July 2012

Print This

Having rejected a media reported $22 a share offer from the company earlier this year, US biotech firm Amylin (Nasdaq: AMLN) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in